AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...

Investing.com -- AstraZeneca’s (ST: AZN) rare disease unit Alexion (NASDAQ: ALXN) said its experimental drug anselamimab ...

An experimental AstraZeneca (NASDAQ:AZN) drug, anselamimab, failed to extend survival or cut heart-related hospitalizations in patients with a rare plasma cell disorder, disappointing hopes it could ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

An investigational AstraZeneca treatment for amyloidosis has failed to show a statistical significance in late-stage trials, the blue chip pharmaceutical group said on Wednesday.

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

AstraZeneca PLC on Wednesday announced that its antibody anselamimab did not achieve statistical significance in the overall patient population, thought it noted a "meaningful improvement" in ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

AstraZeneca PLC closed 20.36% short of its 52-week high of £133.88, which the company achieved on September 3rd.